Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems Description
International healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on average, healthcare spending as a percentage of GDP grew from four percent to 9.6 percent over the same period. Although specifics varied by country, the systemic evolution of international healthcare and reimbursement standards was characterized by two main trends-a shift toward value-based pricing; and more stringent reimbursement standards for new drug evaluations. With this in mind, each country developed its own methods and decision-making processes for reimbursing companies looking to penetrate its market with new innovations. The United Kingdom, Germany, and Japan exemplified this dynamic.
100% money back guarantee if the quality doesn't match the promise
100% Plagiarism Free
If the work we produce contain plagiarism then we payback 1000 USD
Paypal Secure
All your payments are secure with Paypal security.
300 Words per Page
We provide 300 words per page unlike competitors' 250 or 275
Freebies
Free Title Page, Citation Page, References, Exhibits, Revision, Charts
Case study solutions are career defining. Order your custom solution now.
Case Analysis of Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems is a Harvard Business (HBR) Case Study on Innovation & Entrepreneurship , Texas Business School provides HBR case study assignment help for just $9. Texas Business School(TBS) case study solution is based on HBR Case Study Method framework, TBS expertise & global insights. Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems is designed and drafted in a manner to allow the HBR case study reader to analyze a real-world problem by putting reader into the position of the decision maker. Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study will help professionals, MBA, EMBA, and leaders to develop a broad and clear understanding of casecategory challenges. Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems will also provide insight into areas such as – wordlist , strategy, leadership, sales and marketing, and negotiations.
Case Study Solutions Background Work
Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
case study solution
is focused on solving the strategic and operational challenges the protagonist of the case is facing. The challenges involve – evaluation of strategic options, key role of Innovation & Entrepreneurship, leadership qualities of the protagonist, and dynamics of the external environment. The challenge in front of the protagonist, of Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems, is to not only build a competitive position of the organization but also to sustain it over a period of time.
Strategic Management Tools Used in Case Study Solution
The Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study solution requires the MBA, EMBA, executive, professional to have a deep understanding of various strategic management tools such as SWOT Analysis, PESTEL Analysis / PEST Analysis / STEP Analysis, Porter Five Forces Analysis, Go To Market Strategy, BCG Matrix Analysis, Porter Value Chain Analysis, Ansoff Matrix Analysis, VRIO / VRIN and Marketing Mix Analysis.
Texas Business School Approach to Innovation & Entrepreneurship Solutions
In the Texas Business School, Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study solution – following strategic tools are used - SWOT Analysis, PESTEL Analysis / PEST Analysis / STEP Analysis, Porter Five Forces Analysis, Go To Market Strategy, BCG Matrix Analysis, Porter Value Chain Analysis, Ansoff Matrix Analysis, VRIO / VRIN and Marketing Mix Analysis.
We have additionally used the concept of supply chain management and leadership framework to build a comprehensive case study solution for the case – Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Step 1 – Problem Identification of Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems - Harvard Business School Case Study
The first step to solve HBR Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study solution is to identify the problem present in the case. The problem statement of the case is provided in the beginning of the case where the protagonist is contemplating various options in the face of numerous challenges that Reimbursement Percent is facing right now. Even though the problem statement is essentially – “Innovation & Entrepreneurship” challenge but it has impacted by others factors such as communication in the organization, uncertainty in the external environment, leadership in Reimbursement Percent, style of leadership and organization structure, marketing and sales, organizational behavior, strategy, internal politics, stakeholders priorities and more.
Step 2 – External Environment Analysis
Texas Business School approach of case study analysis – Conclusion, Reasons, Evidences - provides a framework to analyze every HBR case study. It requires conducting robust external environmental analysis to decipher evidences for the reasons presented in the Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems.
The external environment analysis of Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems will ensure that we are keeping a tab on the macro-environment factors that are directly and indirectly impacting the business of the firm.
What is PESTEL Analysis? Briefly Explained
PESTEL stands for political, economic, social, technological, environmental and legal factors that impact the external environment of firm in Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study. PESTEL analysis of " Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems" can help us understand why the organization is performing badly, what are the factors in the external environment that are impacting the performance of the organization, and how the organization can either manage or mitigate the impact of these external factors.
How to do PESTEL / PEST / STEP Analysis? What are the components of PESTEL Analysis?
As mentioned above PESTEL Analysis has six elements – political, economic, social, technological, environmental, and legal. All the six elements are explained in context with Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems macro-environment and how it impacts the businesses of the firm.
How to do PESTEL Analysis for Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
To do comprehensive PESTEL analysis of case study – Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems , we have researched numerous components under the six factors of PESTEL analysis.
Political Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Political factors impact seven key decision making areas – economic environment, socio-cultural environment, rate of innovation & investment in research & development, environmental laws, legal requirements, and acceptance of new technologies.
Policy Making Impact on Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Government policies have significant impact on the business environment of any country. The firm in “ Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems ” needs to navigate these policy decisions to create either an edge for itself or reduce the negative impact of the policy as far as possible.
Data safety laws – The countries in which Reimbursement Percent is operating, firms are required to store customer data within the premises of the country. Reimbursement Percent needs to restructure its IT policies to accommodate these changes. In the EU countries, firms are required to make special provision for privacy issues and other laws.
Competition Regulations – Numerous countries have strong competition laws both regarding the monopoly conditions and day to day fair business practices. Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems has numerous instances where the competition regulations aspects can be scrutinized.
Import restrictions on products – Before entering the new market, Reimbursement Percent in case study Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems" should look into the import restrictions that may be present in the prospective market.
Export restrictions on products – Apart from direct product export restrictions in field of technology and agriculture, a number of countries also have capital controls. Reimbursement Percent in case study “ Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems ” should look into these export restrictions policies.
Foreign Direct Investment Policies – Government policies favors local companies over international policies, Reimbursement Percent in case study “ Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems ” should understand in minute details regarding the Foreign Direct Investment policies of the prospective market.
Taxation & Regulation Impact on Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Corporate Taxes – The rate of taxes is often used by governments to lure foreign direct investments or increase domestic investment in a certain sector. Corporate taxation can be divided into two categories – taxes on profits and taxes on operations. Taxes on profits number is important for companies that already have a sustainable business model, while taxes on operations is far more significant for companies that are looking to set up new plants or operations.
Tariffs – Chekout how much tariffs the firm needs to pay in the “ Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems ” case study. The level of tariffs will determine the viability of the business model that the firm is contemplating. If the tariffs are high then it will be extremely difficult to compete with the local competitors. But if the tariffs are between 5-10% then Reimbursement Percent can compete against other competitors.
Government Scheme & Subsidies Impact on Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Research and Development Subsidies and Policies – Governments often provide tax breaks and other incentives for companies to innovate in various sectors of priority. Managers at Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study have to assess whether their business can benefit from such government assistance and subsidies.
Consumer protection – Different countries have different consumer protection laws. Managers need to clarify not only the consumer protection laws in advance but also legal implications if the firm fails to meet any of them.
Political System & Stability, and its Impact on Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Political System and Its Implications – Different political systems have different approach to free market and entrepreneurship. Managers need to assess these factors even before entering the market.
Freedom of Press is critical for fair trade and transparency. Countries where freedom of press is not prevalent there are high chances of both political and commercial corruption.
Corruption level – Reimbursement Percent needs to assess the level of corruptions both at the official level and at the market level, even before entering a new market. To tackle the menace of corruption – a firm should have a clear SOP that provides managers at each level what to do when they encounter instances of either systematic corruption or bureaucrats looking to take bribes from the firm.
Independence of judiciary – It is critical for fair business practices. If a country doesn’t have independent judiciary then there is no point entry into such a country for business.
Government attitude towards trade unions – Different political systems and government have different attitude towards trade unions and collective bargaining. The firm needs to assess – its comfort dealing with the unions and regulations regarding unions in a given market or industry. If both are on the same page then it makes sense to enter, otherwise it doesn’t.
Economic Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Social Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Technological Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Environmental Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Legal Factors that Impact Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems
Step 3 – Industry Specific Analysis
What is Porter Five Forces Analysis
PESTEL stands for political, economic, social, technological, environmental and legal factors that impact the external environment of firm in Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study. PESTEL analysis of " Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems" can help us understand why the organization is performing badly, what are the factors in the external environment that are impacting the performance of the organization, and how the organization can either manage or mitigate the impact of these external factors.
References :: Novartis' Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems case study solution
Amanda is strategy expert at Texas Business School. She is passionate about corporate strategy, competitive strategy, game theory, and business model innovation. You can hire Texas Business School professinoals to revolutionize your strategy & business.
Hurley Dry-Fit Chino Short. Men's chino short. Outseam Length: 19 Dri-FIT Technology helps keep you dry and comfortable. Made with sweat-wicking fabric. Fitted waist with belt loops. Button waist with zip fly provides a classic look and feel .
